Clinical Trials

A hallmark of the Myeloma Institute is a program of clinical trials that challenge the traditional body of thought on disease treatment in order to improve outcomes. The physicians at the Myeloma Institute work in tandem with myeloma scientists to bring the “bench of research to the bedside of the patient” and back again to optimize diagnosis and treatments.


Doug Steward and Susan Panozzo
Clinical Research Department

The “Total Therapy” approach to the treatment of multiple myeloma, with its focus on attacking myeloma from all fronts, has been at the core of successful outcomes at the Myeloma Institute.  Starting with the Total Therapy 1  clinical trial in 1989, outcomes have continued to improve through the incorporation of new agents and adjustments in pre-transplant consolidation and post-transplant maintenance phases of care.

The Myeloma Institute partners with SWOG (formerly the Southwest Oncology Group) on collaborative, multi-center clinical trials, and also participates in pharmaceutical industry trials in order to give patients access to some of the latest pharmaceutical advances.

To view the clinical trials currently open to patient enrollment at the Myeloma Institute, select from the categories below.

Newly Diagnosed Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

Previously Treated Multiple Myeloma

Low-Risk Multiple Myeloma

High-Risk Multiple Myeloma

MGUS and Asymptomatic Multiple Myeloma (AMM)